Ocugen, Inc.
NASDAQ:OCGNBiotechnology
+$0.03 today
- Market cap
- $250.82M
- Beta
- 2.21
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$0.22
Volume 5.83M
Average 7.51M
OCGN Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Ocugen, Inc.NASDAQ: OCGN
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows in line with its trailing trend
Q1 FY2026 net income of $19.18M (cash outflow) rose 24.9% year over year, in line with the +24.7% change in trailing-twelve-month net income. Sequentially, it rose 8.3% from the prior quarter. Over 3 fiscal years it compounded at -7.9% a year.
Context
- Net income amounted to 1537.4% of revenue in FY2025, up 204.4 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$59.96M (-11.6%) for the fiscal year ending Dec 2026, a slowdown from the +25.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$19.18M+8.3% QoQ
- Last fiscal yearDec 2025
- -$67.85M+25.5% YoY
- LTMMar 2026
- -$71.67M+24.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +24.9% | +22.7% | -2.2 pp |
| 1 year | +25.5% | -11.6% | -37.1 pp |
| 3-year CAGR | -7.9% | -59.9% | -52.0 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (67.85M) USD
- Year-over-year change
- -25.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (67.85M) | -25.5% |
| FY2024 | 2024-12-31 | (54.05M) | +14.3% |
| FY2023 | 2023-12-31 | (63.08M) | +27.3% |
| FY2022 | 2022-12-31 | (86.8M) | -48.7% |
| FY2021 | 2021-12-31 | (58.37M) | — |
Net Income vs competitors
How OCGN compares with its peers on the latest reported figures
- OCGN's LTM Mar 2026 net income of $71.67M is the 7th largest of the 10 companies compared; the peer median is $76.12M.
- Its year-over-year change of +24.7% is the 5th highest of 10, against a peer median of +23.5%.
- Net income amounts to 1605.2% of revenue for OCGN, versus a peer median of 433.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $438.96M | +92.9% | +29.5% | 5933.5% |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $222.39M | -13.8% | +21.9% | — |
| LTM Mar 2026 | $136.99M | -8.6% | -3.2% | 173.0% | |
| LTM Mar 2026 | $98.64M | +22.0% | +17.9% | — | |
| LTM Mar 2026 | $81.36M | +148.9% | -73.6% | 822.4% | |
| LTM Mar 2026 | $76.12M | +14824.7% | -12.0% | — | |
| LTM Mar 2026 | $71.67M | +24.7% | -7.9% | 1605.2% | |
| LTM Mar 2026 | $68.17M | +23.5% | +19.2% | — | |
| LTM Mar 2026 | $64.01M | +294.9% | +34.1% | 433.1% | |
| LTM Mar 2026 | $26.09M | -85.3% | -21.0% | 37.5% | |
| Peer median (excluding OCGN) | $76.12M | +23.5% | +17.9% | 433.1% | |
Competitors are the stored peer set for OCGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (58.37M) | (86.8M) | (63.08M) | (54.05M) | (67.85M) |
| Depreciation & Amortization | 229K | 480K | 704K | 1.97M | 2.39M |
| Deferred Income Tax | (52K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.96M | 10.54M | 9.22M | 7.43M | 7.71M |
| Change in Working Capital | 2.49M | 9.2M | (13.16M) | 3.67M | (523K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.5M | 0 | 0 | 0 | 0 |
| Other Working Capital | (1.01M) | 9.2M | (13.16M) | 3.67M | (523K) |
| Other Non-Cash Items | 799K | 6.51M | 4.26M | (1.15M) | 1.31M |
| Operating Cash Flow | (47.94M) | (60.08M) | (62.05M) | (42.14M) | (56.96M) |
| Capital Expenditures | (939K) | (4.46M) | (10.48M) | (3.39M) | (185K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (13.27M) | (3.95M) | 0 | 0 |
| Sales of Investments | 0 | 0 | 17.5M | 0 | 0 |
| Other Investing Activities | (877K) | 761K | 0 | 0 | (126K) |
| Investing Cash Flow | (1.82M) | (16.97M) | 3.08M | (3.39M) | (311K) |
| Debt Repayment | (10K) | 500K | 500K | 30M | (1M) |
| Common Stock Issued | 129.21M | 59.57M | 20.8M | 38.56M | 18.33M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (8.53M) | (592K) | (68K) | (3.7M) | 0 |
| Financing Cash Flow | 120.68M | 59.48M | 20.88M | 64.86M | 17.33M |
| Effect of Forex Changes | (325) | 25K | (5K) | 28K | 13K |
| Net Change in Cash | 70.92M | (17.55M) | (38.1M) | 19.36M | (39.93M) |
| Free Cash Flow | (48.88M) | (64.54M) | (72.53M) | (45.53M) | (57.15M) |
Ocugen, Inc.
NASDAQ:OCGN
Intrinsic Alpha fair value
Locked
Current Price
$0.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.